Indications and collaborations, page-4

G’day Rae.  It actually says that there was weight loss on those trials.  Maybe not too relevant for Alzheimer’s.  But definitely useful for Type 2 diabetes where 90% of sufferers are overweight or obese.

Extract from the RO151 and RO838 diabetes trial as an example....

“....RESULTS: Despite the short treatment duration, both RO-151 and RO-838 showed trends for improved HbA1c and consistent reductions in body weight (-0.86 to -1.67 kg) exceeding those observed with placebo (-0.28 kg, p = 0.019 for 200 mg RO-151 vs. placebo)....”